Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Healthy

Interventions

DRUG

Hydrocodone Bitartrate

Hydrocodone bitartrate oral suspension

DRUG

Doxapram Hydrochloride

Doxapram hydrocholoride oral suspension

Trial Locations (1)

Cleveland Clinic Main Campus, Cleveland

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Quivive Pharma, Inc.

INDUSTRY

NCT06585163 - Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension | Biotech Hunter | Biotech Hunter